Financing ·
On September 2, 2026, Clearmind Medicine Inc. entered into a conversion agreement with its CLA Investors to convert…
CMNDClearmind Medicine Inc.
On September 2, 2026, Clearmind Medicine Inc. entered into a conversion agreement with its CLA Investors to convert $687,500 in principal plus accrued interest totaling $696,079.50 from convertible promissory notes into common shares at an agreed price of $1.00 per share. The company also amended the floor price provision attached to its Securities Purchase Agreements to $1.00 per common share. Clearmind Medicine Inc. operates in the biotechnology industry, developing treatments for neurological and psychiatric disorders.